Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Treatments and follow-up duration in the TAK >40 and TAK ≤40 groups

From: Fewer subsequent relapses and lower levels of IL-17 in Takayasu arteritis developed after the age of 40 years

Variable TAK >40, n = 20 TAK ≤40, n = 23 P value
Initial dose of prednisolone, mg/day (IQR) 30 (15–40) 40 (30–45) 0.024*
Initial dose of prednisolone, mg/day (IQR) 0.55 (0.28–0.82) 0.80 (0.59–0.94) 0.048*
Pulsed methylprednisolone as an initial therapy 2 (10) 7 (30) 0.142
Methotrexate with prednisolone before relapses, n (%), mg/week (IQR) 7 (35), 8 (6–8) 9 (39), 10 (7–13) 1.00
Cyclosporine with prednisolone before relapses, n (%), mg/day (IQR) 1 (5), 150 4 (17), 160 (105–238) 0.35
Tacrolimus with prednisolone before relapses, n (%), mg/day (IQR) 1 (5), 3.0 1 (4), 0.5 1.00
Infliximab, n (%) 0 (0) 5 (22) 0.051
Adalimumab, n (%) 0 (0) 1 (4) 1.00
Tocilizumab, n (%) 1 (5) 1 (4) 1.00
Reduction rate of prednisolone dose, mg/month (IQR) 2.7 (2.3–3.0) 2.8 (2.4–2.9) 0.87
Dose of prednisolone at relapse, mg/day (IQR) 10 (8–16) 15 (11–20) 0.11
Follow-up duration, months (IQR) 70 (25–133) 55 (28–115) 0.94
  1. TAK >40 Takayasu arteritis onset after age 40 years; TAK ≤40 TAK onset at age 40 years or younger. *P < 0.05